

February 12, 2025

To,

Listing Operation Department
BSE Limited (BSE)
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400 001

Listing Compliance Department
The National Stock Exchange of India Limited (NSE)
05th Floor, Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Bandra (E) Mumbai - 400 051

Scrip Code: **544119**

Symbol: **RPTECH**

Sub: Declaration of Unaudited Standalone and Consolidated Financial Results for quarter and nine months ended December 31, 2024

Ref.: Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sir/Madam,

Pursuant to Regulations 30 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulation") as amended from time to time, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. February 12, 2025 has, *inter alia*, approved the following:

1. Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024 ("Unaudited Financial Results"). Copy of the Unaudited Financial Results (Standalone & Consolidated) of the Company along with Limited Review Report issued by Joint Statutory Auditors of the Company, is enclosed herewith as **(Annexure-I)**

Further, please find enclosed the following:

2. Pursuant to Regulation 32(1) the Listing Regulations, a statement indicating the utilization of issue proceeds of initial public offer and statement indicating Nil deviation and variation **(Annexure-II)**; and
3. Monitoring Agency Report as required under Regulation 32(6) of the Listing Regulation **(Annexure-III)**;

The Meeting commenced at 02:30 P.M. (IST) and concluded at 04:30 p.m. (IST)

Rashi Peripherals Limited

(formerly known as Rashi Peripherals Private Limited)

Regd. Office: Ariisto House, 5th Floor, N S Phadke Road, Andheri East, Mumbai, Maharashtra – 400069, India
• Tel: +91-22-6177 1771 | Fax +91-22-61771999 • www.rptechindia.com | CIN: L30007MH1989PLC051039

The above announcement is also being made available on the website of the Company at www.rptechindia.com/investor.

You are requested to kindly take the same on record

Thankyou.

Your faithfully,
For **RASHI PERIPHERALS LIMITED**
(formerly known Rashi Peripherals Private Limited)

Hinal Shah
Company Secretary
& Compliance Officer

Encl.: As above

Rashi Peripherals Limited
(formerly known as Rashi Peripherals Private Limited)

Regd. Office: Ariisto House, 5th Floor, N S Phadke Road, Andheri East, Mumbai, Maharashtra – 400069, India
• Tel: +91-22-6177 1771 | Fax +91-22-61771999 • www.rptechindia.com | CIN: L30007MH1989PLC051039

Deloitte Haskins & Sells LLP
Chartered Accountants
One International Centre, Tower 3,
31st Floor, Senapati Bapat Marg,
Elphinstone Road (West),
Mumbai 400013
Maharashtra, India
Phone: +91 22 6185 4000
Fax: +91 22 6185 4101

Pipara & Co LLP
Chartered Accountants
Tradelink Building, #3, 7th Floor (1303),
E Wing, A Block, Kamala Mills Compound,
Senapati Bapat Marg,
Mumbai 400013
Maharashtra, India

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
STANDALONE FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
RASHI PERIPHERALS LIMITED (FORMERLY KNOWN AS RASHI PERIPHERALS
PRIVATE LIMITED)**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **RASHI PERIPHERALS LIMITED** (formerly known as Rashi Peripherals Private Limited) ("the Company"), which includes branch located outside India for the quarter and nine months ended December 31, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the Branch Auditor as referred in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial information of a branch located outside India included in the Statement whose interim financial information reflect total revenue of Rs.18.98 million and Rs.744.19 million for the quarter and nine months ended December 31, 2024 respectively, total net profit / (loss) after tax of Rs.(6.09) million and Rs.18.18 million for the quarter and nine months ended December 31, 2024 and



The interim financial information of this branch has been reviewed by the branch auditors whose report has been furnished to us, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these branch, is based solely on the report of such branch auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

| | |
|---|--|
| <p>For Deloitte Haskins & Sells LLP Chartered Accountants (Firm's Registration No. 117366W/W-100018)</p> <p><i>Pallavi Sharma</i></p> <p>Pallavi Sharma Partner Membership No. 113861 UDIN: 25113861BMJIAB8487 Place: Mumbai Date: February 12, 2025</p>  | <p>For Pipara & Co LLP Chartered Accountants (Firm's Registration No. 107929W/W-100219)</p> <p><i>Bhawik Madrecha</i></p> <p>Bhawik Madrecha Partner Membership No. 163412 UDIN: 25163412BMVWIX2959 Place: Mumbai Date: February 12, 2025</p>  |
|---|--|

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2024

Rupees in millions unless otherwise specified

| Particulars | Quarter Ended | | | Nine Months Ended | | Year Ended | |
|-----------------|---|-----------------------|----------------------|----------------------|----------------------|------------------|--------------------|
| | December 31, 2024 | September 30, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2023 | March 31, 2024 | |
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | |
| INCOME | | | | | | | |
| I | Revenue from Operations | 26,511.45 | 35,711.17 | 24,813.58 | 1,03,800.77 | 78,696.76 | 1,07,309.95 |
| II | Other Income | 484.75 | 49.36 | 43.70 | 572.53 | 111.74 | 163.26 |
| III | Total Income (I + II) | 26,996.20 | 35,760.53 | 24,857.28 | 1,04,373.30 | 78,808.50 | 1,07,473.21 |
| EXPENSES | | | | | | | |
| IV | (a) Purchases of stock-in-trade | 22,897.44 | 36,337.71 | 20,921.79 | 99,545.43 | 78,526.65 | 1,05,258.80 |
| | (b) Changes in inventories of stock-in-trade | 2,180.50 | (2,372.31) | 2,661.53 | (859.58) | (3,779.31) | (3,227.85) |
| | (c) Employee benefits expense | 406.76 | 390.83 | 349.26 | 1,204.15 | 1,016.55 | 1,389.29 |
| | (d) Finance costs | 227.83 | 172.45 | 298.59 | 537.95 | 837.92 | 1,067.51 |
| | (e) Depreciation and amortisation expenses | 39.76 | 38.39 | 45.20 | 114.99 | 128.11 | 173.22 |
| | (f) Other expenses | 831.76 | 380.43 | 237.92 | 1,880.37 | 715.05 | 1,058.35 |
| | Total Expenses (IV) | 26,584.05 | 34,947.50 | 24,514.29 | 1,02,423.31 | 77,444.97 | 1,05,719.32 |
| V | Profit before tax (III - IV) | 412.15 | 813.03 | 342.99 | 1,949.99 | 1,363.53 | 1,753.89 |
| VI | Tax expense | 103.87 | 129.73 | 87.84 | 411.19 | 353.67 | 420.01 |
| VII | Profit after tax (V - VI) | 308.28 | 683.30 | 255.15 | 1,538.80 | 1,009.86 | 1,333.88 |
| VIII | Other comprehensive income | | | | | | |
| A | Items that will not be reclassified to profit or loss | | | | | | |
| (a) | (i) Remeasurement of defined benefits plan - (loss)/gain | 1.10 | 1.10 | (1.29) | 3.30 | (3.88) | 4.35 |
| | (ii) Income tax (expenses)/benefits on remeasurement of defined benefits plan | 0.28 | 0.27 | (0.33) | 0.83 | (0.98) | 1.09 |
| (b) | (i) Net fair value loss on investments in equity shares through OCI | - | - | - | - | (15.55) | (56.12) |
| | (ii) Income tax benefits on net fair value loss on investments in equity shares through OCI | - | - | - | - | 3.91 | 9.77 |
| | Total other comprehensive income | 1.38 | 1.37 | (1.62) | 4.13 | (16.50) | (40.91) |
| IX | Total comprehensive income (VII + VIII) | 309.66 | 684.67 | 253.53 | 1,542.93 | 993.36 | 1,292.97 |
| X | Paid-up equity share capital (Face Value - Rs. 5/- per share) | 329.50 | 329.50 | 208.92 | 329.50 | 208.92 | 329.50 |
| XI | Other equity | - | - | - | - | - | 14,982.94 |
| XII | Earnings per Equity Share: (Face Value Rs. 5/- per share) (Rs.)* | | | | | | |
| | Basic | 4.68 | 10.37 | 6.11 | 23.35 | 24.17 | 29.41 |
| | Diluted | 4.68 | 10.37 | 6.11 | 23.35 | 24.17 | 29.41 |

* Basic and Diluted EPS for all periods, except for the year ended March 31, 2024 are not annualised.



Notes to the Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2024

- The above statement of standalone unaudited financial results of Rashi Peripherals Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ("Ind AS") 34 - "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- The standalone financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 12, 2025. The Statutory Auditors of the Company carried out the review of the standalone financial results for the quarter and nine months ended December 31, 2024.
- During the year ended March 31, 2024 the Company had completed IPO comprising of fresh issue of 1,92,92,604 equity shares of face value Rs. 5/- each at an issue price of Rs. 311/- per share for cash consideration aggregating to Rs. 6,000 millions. Pursuant to IPO, equity shares of the Company were listed on BSE Limited and National Stock Exchange (hereinafter referred to as "Stock Exchanges") w.e.f. February 14, 2024.
 The Company had received an amount of Rs. 5,541.41 millions (net of IPO expenses of Rs. 458.59 millions including taxes) from proceeds out of fresh issue of equity shares. The utilisation of net IPO proceeds is summarised below.

Rupees in millions

| Objects of the Issue as per Prospectus | Amount to be financed from Net Proceeds as per Prospectus | Amount utilised from Net IPO Proceeds upto December 31, 2024 | Unutilised amount as on December 31, 2024 |
|---|---|--|---|
| (a) Prepayment or scheduled re-payment of all or a portion of certain outstanding borrowings availed by the Company | 3,260.00 | 3,260.00 | - |
| (b) Funding working capital requirements of the Company | 2,200.00 | 2,200.00 | - |
| (c) General corporate purpose | 81.41 | 18.57 | 62.84 |
| Total | 5,541.41 | 5,478.57 | 62.84 |

The IPO expenses incurred of Rs. 391.06 millions (excluding taxes) has been adjusted against securities premium during the year ended March 31, 2024.

- The Company operates in a single operating segment namely Computer Systems, Software & Peripherals, Mobiles. The Board of Directors is the Chief Operating Decision Maker (the "CODM") of the Company and makes operating decisions, assesses financial performance and allocates resources based upon discrete financial information. Since the Company operate in a single operating segment, separate segment reporting has not been made under Indian Accounting Standard ("Ind AS") 108 -"Operating Segment". Further, the operation of the Company comprises of geographical segment as disclosed below.

Revenue disaggregation by geography is as follows

Rupees in millions

| Particulars | Quarter Ended | | | Nine Months Ended | | Year Ended |
|--------------|-------------------|--------------------|-------------------|--------------------|-------------------|--------------------|
| | December 31, 2024 | September 30, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2023 | March 31, 2024 |
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| India | 26,340.17 | 35,521.91 | 24,269.79 | 1,02,854.54 | 77,431.16 | 1,05,416.93 |
| Overseas | 171.28 | 189.26 | 543.79 | 946.23 | 1,265.60 | 1,893.02 |
| Total | 26,511.45 | 35,711.17 | 24,813.58 | 1,03,800.77 | 78,696.76 | 1,07,309.95 |

For and on behalf of the Board of Directors

Rashi Peripherals Limited

Krishna Kumar Choudhary

Krishna Kumar Choudhary
 Chairman & Wholetime Director
 DIN: 00215919



Place: Mumbai
 Date: February 12, 2025



Deloitte Haskins & Sells LLP
Chartered Accountants
One International Centre, Tower 3,
31st Floor, Senapati Bapat Marg,
Elphinstone Road (West),
Mumbai 400013
Maharashtra, India
Phone: +91 22 6185 4000
Fax: +91 22 6185 4101

Pipara & Co LLP
Chartered Accountants
Tradelink Building, #3, 7th Floor (1303),
E Wing, A Block, Kamala Mills Compound,
Senapati Bapat Marg,
Mumbai 400013
Maharashtra, India

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
CONSOLIDATED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
RASHI PERIPHERALS LIMITED (FORMERLY KNOWN AS RASHI PERIPHERALS
PRIVATE LIMITED)**


1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Rashi Peripherals Limited** (formerly known as Rashi Peripherals Private Limited) ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended December 31, 2024 ("the Statement") which includes the branch of the Group located outside India being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

| Name of the Entity | Relationship |
|-----------------------------------|--------------------|
| Rashi Peripherals Limited | Parent Company |
| Rashi Peripherals Pte Ltd | Subsidiary Company |
| Znet Technologies Private Limited | Subsidiary Company |

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as



6. We did not review the interim financial information of a branch included in the standalone unaudited financial results of the Parent included in the Group, whose interim financial information reflect, total revenue of Rs.18.98 million and Rs.744.19 million for the quarter and nine months ended December 31, 2024 respectively, total net profit / (loss) after tax of Rs.(6.09) million and Rs.18.18 million for the quarter and nine months ended December 31, 2024 and total comprehensive income / (loss) of Rs.(6.09) million and Rs.18.18 million for the quarter and nine months ended December 31, 2024, as considered in the respective standalone unaudited financial information/ financial results of the entities included in the Group. The interim financial information of this branch has been reviewed by the branch auditors whose report has been furnished to us and our conclusion in so far as it relates to the amounts and disclosures included in respect of this branch is based solely on the report of such branch auditors and the procedures performed by us as stated in paragraph 3 above.

We did not review the interim financial results of two subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs.1,753.69 million and Rs.4,197.60 million for the quarter and nine months ended December 31, 2024 respectively, total net profit after tax of Rs.11.35 million and Rs.27.81 million for the quarter and nine months ended December 31, 2024 respectively and total comprehensive income of Rs.3.74 million and Rs.20.53 million for the quarter and nine months ended December 31, 2024 respectively, as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

| | |
|--|---|
| <p>For Deloitte Haskins & Sells LLP Chartered Accountants (Firm's Registration No. 117366W/W-100018)</p> <p> Pallavi Sharma Partner Membership No. 113861 UDIN: 25113861BMTIAC1433 Place: Mumbai Date: February 12, 2025</p> <p></p> | <p>For Pipara & Co LLP Chartered Accountants (Firm's Registration No. 107929W/W-100219)</p> <p> Bhawik Madrecha Partner Membership No. 163412 UDIN: 25163412BMNWIY5047 Place: Mumbai Date: February 12, 2025</p> <p></p> |
|--|---|

Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2024

Rupees in millions unless otherwise specified

| | Particulars | Quarter Ended | | | Nine Months Ended | | Year Ended |
|------|---|----------------------|-----------------------|----------------------|----------------------|----------------------|--------------------|
| | | December 31, 2024 | September 30, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2023 | March 31, 2024 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| | INCOME | | | | | | |
| I | Revenue from Operations | 28,263.07 | 37,061.71 | 26,239.61 | 1,07,995.59 | 80,924.71 | 1,10,946.98 |
| II | Other Income | 484.21 | 54.80 | 43.16 | 583.95 | 90.66 | 143.97 |
| III | Total Income (I + II) | 28,747.28 | 37,116.51 | 26,282.77 | 1,08,579.54 | 81,015.37 | 1,11,090.95 |
| | EXPENSES | | | | | | |
| IV | (a) Purchases of stock-in-trade | 25,225.64 | 37,454.54 | 23,307.10 | 1,04,157.40 | 81,597.83 | 1,08,329.91 |
| | (b) Changes in inventories of stock-in-trade | 1,465.03 | (2,256.15) | 1,555.40 | (1,645.16) | (5,073.26) | (3,314.05) |
| | (c) Employee benefits expense | 431.47 | 413.83 | 381.99 | 1,274.56 | 1,117.26 | 1,517.28 |
| | (d) Finance costs | 228.55 | 172.66 | 299.09 | 539.88 | 838.99 | 1,071.39 |
| | (e) Depreciation and amortisation expenses | 44.01 | 42.31 | 49.12 | 127.00 | 139.75 | 188.79 |
| | (f) Other expenses | 926.10 | 459.95 | 355.12 | 2,143.53 | 1,033.74 | 1,484.89 |
| | Total Expenses (IV) | 28,320.80 | 36,287.14 | 25,947.82 | 1,06,597.21 | 79,654.31 | 1,09,278.21 |
| V | Profit before tax (III - IV) | 426.48 | 829.37 | 334.95 | 1,982.33 | 1,361.06 | 1,812.74 |
| | Add : Exceptional Item (Refer note 6) | - | - | - | - | - | 103.82 |
| VI | Profit after exceptional item | 426.48 | 829.37 | 334.95 | 1,982.33 | 1,361.06 | 1,916.56 |
| VII | Tax expense | 105.78 | 130.70 | 87.16 | 412.59 | 393.09 | 477.98 |
| VIII | Profit after tax (VI - VII) | 320.70 | 698.67 | 247.79 | 1,569.74 | 967.97 | 1,438.58 |
| IX | Other comprehensive income | | | | | | |
| | A Items that will not be reclassified to profit or loss | | | | | | |
| | (a) (i) Remeasurement of defined benefits plan - (loss)/gain | 1.08 | 1.08 | (1.29) | 3.24 | (5.13) | 4.27 |
| | (ii) Income tax (expenses)/benefits on remeasurement of defined benefits plan | 0.29 | 0.27 | (0.32) | 0.85 | (0.65) | 1.11 |
| | (b) (i) Net fair value loss on investments in equity shares through OCI | - | - | - | - | (15.55) | (56.12) |
| | (ii) Income tax benefits on net fair value loss on investments in equity shares through OCI | - | - | - | - | 3.91 | 9.77 |
| | B Items that may be reclassified subsequently to profit or loss | | | | | | |
| | (a) Foreign exchange differences on translation of foreign operations | (7.60) | 0.37 | (6.83) | (7.24) | (6.39) | 1.64 |
| | Total other comprehensive income | (6.23) | 1.72 | (8.44) | (3.15) | (23.81) | (39.33) |
| X | Total comprehensive income (VIII + IX) | 314.47 | 700.39 | 239.35 | 1,566.59 | 944.16 | 1,399.25 |
| XI | Profit attributable to the :- | | | | | | |
| | Owners of the Company | 318.38 | 697.36 | 252.22 | 1,567.82 | 1,014.34 | 1,412.21 |
| | Non-Controlling Interests | 2.32 | 1.31 | (4.43) | 1.92 | (46.37) | 26.37 |
| XII | Other Comprehensive Income attributable to the :- | | | | | | |
| | Owners of the Company | (4.38) | 1.64 | (6.78) | (1.37) | (21.81) | (39.70) |
| | Non-Controlling Interests | (1.85) | 0.08 | (1.66) | (1.78) | (2.00) | 0.37 |
| XIII | Total Comprehensive Income attributable to the :- | | | | | | |
| | Owners of the Company | 314.00 | 699.00 | 245.44 | 1,566.45 | 992.53 | 1,372.51 |
| | Non-Controlling Interests | 0.47 | 1.39 | (6.09) | 0.14 | (48.37) | 26.74 |
| XIV | Paid-up equity share capital (Face Value - Rs. 5/- per share) | 329.50 | 329.50 | 208.92 | 329.50 | 208.92 | 329.50 |
| XV | Other equity | - | - | - | - | - | 15,176.34 |
| XVI | Earnings per Equity Share: (Face Value Rs. 5/-per share) (Rs.)* | | | | | | |
| | Basic | 4.83 | 10.58 | 6.04 | 23.79 | 24.28 | 31.14 |
| | Diluted | 4.83 | 10.58 | 6.04 | 23.79 | 24.28 | 31.14 |

* Basic and Diluted EPS for all periods, except for the year ended March 31, 2024 are not annualised.



Notes to the Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2024

- The above statement of consolidated unaudited financial results of Rashi Peripherals Limited ("the Parent Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ("Ind AS") 34 - "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- The consolidated financial results of the Parent Company have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 12, 2025. The Statutory Auditors of the Parent Company carried out the review of the consolidated financial results for the quarter and nine months ended December 31, 2024.
- During the year ended March 31, 2024 the Parent Company had completed IPO comprising of fresh issue of 1,92,92,604 equity shares of face value Rs. 5/- each at an issue price of Rs. 311/- per share for cash consideration aggregating to Rs. 6,000 millions. Pursuant to IPO, equity shares of the Parent Company were listed on BSE Limited and National Stock Exchange (hereinafter referred to as "Stock Exchanges") w.e.f. February 14, 2024.

The Parent Company had received an amount of Rs. 5,541.41 millions (net of IPO expenses of Rs. 458.59 millions including taxes) from proceeds out of fresh issue of equity shares. The utilisation of net IPO proceeds is summarised below.

Rupees in millions

| Objects of the Issue as per Prospectus | Amount to be financed from Net Proceeds as per Prospectus | Amount utilised from Net IPO Proceeds upto December 31, 2024 | Unutilised amount as on December 31, 2024 |
|--|---|--|---|
| (a) Prepayment or scheduled re-payment of all or a portion of certain outstanding borrowings availed by the Parent Company | 3,260.00 | 3,260.00 | - |
| (b) Funding working capital requirements of the Parent Company | 2,200.00 | 2,200.00 | - |
| (c) General corporate purpose | 81.41 | 18.57 | 62.84 |
| Total | 5,541.41 | 5,478.57 | 62.84 |

The IPO expenses incurred of Rs. 391.06 millions (excluding taxes) has been adjusted against securities premium during the year ended March 31, 2024.

- The Group operates in a single operating segment namely Computer Systems, Software & Peripherals, Mobiles. The Board of Directors is the Chief Operating Decision Maker (the "CODM") of the Group and makes operating decisions, assesses financial performance and allocates resources based upon discrete financial information. Since the Parent Company operate in a single operating segment, separate segment reporting has not been made under Indian Accounting Standard ("Ind AS") 108 - "Operating Segment". Further, the operation of the Group comprises of geographical segment as disclosed below.

Revenue disaggregation by geography is as follows

Rupees in millions

| Particulars | Quarter Ended | | | Nine Months Ended | | Year Ended |
|--------------|-------------------|--------------------|-------------------|--------------------|-------------------|--------------------|
| | December 31, 2024 | September 30, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2023 | March 31, 2024 |
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| India | 26,749.69 | 36,188.31 | 24,443.64 | 1,04,369.91 | 78,053.64 | 1,06,913.86 |
| Overseas | 1,513.38 | 873.40 | 1,795.97 | 3,625.68 | 2,871.07 | 4,033.12 |
| Total | 28,263.07 | 37,061.71 | 26,239.61 | 1,07,995.59 | 80,924.71 | 1,10,946.98 |



- 5 The Standalone Financial Results for the quarter ended December 31, 2024 are summarized below and detailed financial report is also available on the Stock Exchange website, www.nseindia.com, www.bseindia.com and Parent Company's website www.rptechindia.com

Rupees in millions

| Particulars | Quarter Ended | | | Nine Months Ended | | Year Ended |
|-------------------------|----------------------|-----------------------|----------------------|----------------------|----------------------|----------------|
| | December 31, 2024 | September 30, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2023 | March 31, 2024 |
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| Revenue from Operations | 26,511.45 | 35,711.17 | 24,813.58 | 1,03,800.77 | 78,696.76 | 1,07,309.95 |
| Profit before tax | 412.15 | 813.03 | 342.99 | 1,949.99 | 1,363.53 | 1,753.89 |
| Profit after tax | 308.28 | 683.30 | 255.15 | 1,538.80 | 1,009.86 | 1,333.88 |

- 6 During the year ended March 31, 2024, a subsidiary of the Company had entered into an agreement viz.; "Agreement for Non-compete and Purchase of Business Assets" dated February 7, 2024, for transfer of certain business assets considered as non-compete assets, for a total consideration of Rs. 129.78 millions. Out of the total consideration, Rs. 103.82 millions was receivable within 45 days of the agreement date and the remaining consideration of Rs. 25.96 millions is receivable after fulfilment of certain conditions as per the agreement, which are yet to be fulfilled. Accordingly, an amount of Rs. 103.82 millions is recognized in the books of account during the year ended March 31, 2024, based on the terms and conditions of the above mentioned agreement and has been disclosed as exceptional item in the statement of consolidated financial results.

For and on behalf of the Board of Directors

Rashi Peripherals Limited



Krishna Kumar Choudhary
Chairman & Wholtime Director
DIN: 00215919




Place: Mumbai

Date: February 12, 2025



Annexure-II

| Statement of Deviation / Variation in utilisation of funds raised | | | | | | |
|--|---|---|-----------------------------|-----------------------------|--|----------------|
| Name of listed entity | | RASHI PERIPHERALS LIMITED | | | | |
| Mode of Fund Raising | | Initial Public Offer / Rights Issues / Preferential Issues / QIP / Others | | | | |
| Date of Raising Funds | | February 14, 2024 | | | | |
| Amount Raised | | ₹ 600.00 Crore | | | | |
| Report filed for Quarter ended | | December 31, 2024 | | | | |
| Monitoring Agency | | Applicable | | | | |
| Monitoring Agency Name, if applicable | | CARE RATINGS LIMITED | | | | |
| Is there a Deviation / Variation in use of funds raised | | Nil | | | | |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | | Not Applicable | | | | |
| If Yes, Date of shareholder Approval | | Not Applicable | | | | |
| Explanation for the Deviation / Variation | | Not Applicable | | | | |
| Comments of the Audit Committee after review | | None | | | | |
| Comments of the auditors, if any | | None | | | | |
| Objects for which funds have been raised and where there has been a deviation, in the following table: | | Not Applicable | | | | |
| Original Object | Modified Object, if any | Original Allocation (₹ in Crore) | Modified allocation, if any | Funds Utilised (₹ in Crore) | Amount of Deviation/Variation for the quarter according to applicable object | Remarks if any |
| 1. Prepayment or scheduled re-payment of all or a portion of certain outstanding borrowings availed by our Company; | Nil | 326.00 | Nil | 326.00 | Nil | NA |
| 2. Funding working capital requirements of our Company; and | Nil | 220.00 | Nil | 220.00 | Nil | NA |
| 3. General corporate purposes | Nil | 8.14 | Nil | 1.86 | Nil | NA |
| Deviation or variation could mean: | | | | | | |
| (a) Deviation in the objects or purposes for which the funds have been raised or | | | | | | |
| (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or | | | | | | |
| (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc. | | | | | | |
| Signature: |  | | | | | |
| Name of Signatory | Himanshu Shah | | | | | |
| Designation | Chief Financial Officer | | | | | |

Rashi Peripherals Limited

(formerly known as Rashi Peripherals Private Limited)

Regd. Office: Aristo House, 5th Floor, N S Phadke Road, Andheri East, Mumbai, Maharashtra – 400069, India
• Tel: +91-22-6177 1771 | Fax +91-22-61771999 • www.rptechindia.com | CIN: L30007MH1989PLC051039

No. CARE/HO/GEN/2024-25/1121

**The Board of Directors
Rashi Peripherals Limited**

Ariisto House, 5th Floor,
Junction of N.S.Phadke Road,
Telli Gali, Andheri (E),
Mumbai- 400 069, Maharashtra,
India.

February 12, 2025

Dear Sir/Ma'am,

**Monitoring Agency Report for the quarter ended December 31, 2024 - in relation to the IPO of
Rashi Peripherals Limited ("the Company")**

We write in our capacity of Monitoring Agency for the Rights Issue for the amount aggregating to Rs. 600 crore of the Company and refer to our duties cast under Section 41 of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations.

In this connection, we are enclosing the Monitoring Agency Report for the quarter ended December 31, 2024 as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated April 10, 2024.

Request you to kindly take the same on records.

Thanking you,
Yours faithfully,



Sonal Bhageria
Assistant Director
Sonal.bhageria@careedge.in



CARE Ratings Limited

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai
Phone: +91-22-6754 3456 • www.careedge.in

CIN-L67190MH1993PLC071691

Report of the Monitoring Agency

Name of the issuer: Rashi Peripherals Limited

For quarter ended: December 31, 2024

Name of the Monitoring Agency: CARE Ratings Limited

(a) Deviation from the objects: Nil

(b) Range of Deviation: Not applicable

Declaration:

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.

Signature:

Name and designation of the Authorized Signatory: Sonal Bhageria

Designation of Authorized person/Signing Authority: Assistant Director

CARE Ratings Limited

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai
Phone: +91-22-6754 3456 • www.careedge.in

CIN-L67190MH1993PLC071691

1) Issuer Details:

Name of the issuer : Rashi Peripherals Limited
Name of the promoter : Krishna Kumar Choudhary, Sureshkumar Pansari, Kapal Suresh Pansari, Keshav Krishna Kumar Choudhary, Chaman Pansari, Krishna Kumar Choudhary (HUF), and Suresh M Pansari (HUF).
Industry/sector to which it belongs : ICT Product Distribution

2) Issue Details

Issue Period : 02/07/2024 to 02/09/2024
Type of issue (public/rights) : IPO
Type of specified securities : Equity Shares
IPO Grading, if any : Not Applicable
Issue size (in crore) : Rs. 600 crores



CARE Ratings Limited

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai
Phone: +91-22-6754 3456 • www.careedge.in

CIN-L67190MH1993PLC071691



3) Details of the arrangement made to ensure the monitoring of issue proceeds:

| Particulars | Reply | Source of information / certifications considered by Monitoring Agency for preparation of report | Comments of the Monitoring Agency | Comments of the Board of Directors |
|---|--------------------------------|--|---|------------------------------------|
| Whether all utilization is as per the disclosures in the Offer Document? | Yes | CA Certificate* Bank Statement | Nil | Nil |
| Whether shareholder approval has been obtained in case of material deviations# from expenditures disclosed in the Offer Document? | Not applicable as no deviation | Company declaration | Nil | Nil |
| Whether the means of finance for the disclosed objects of the issue have changed? | No | Company declaration | Nil | Nil |
| Is there any major deviation observed over the earlier monitoring agency reports? | Not applicable | Not Applicable | No deviations observed from the last monitoring agency report | Nil |
| Whether all Government/statutory approvals related to the object(s) have been obtained? | Not applicable | Company declaration (RHP In-principal approval) | Not Applicable | Nil |
| Whether all arrangements pertaining to technical assistance/collaboration are in operation? | Yes | Company declaration (BSE & NSE Software purchased) | Not Applicable | Nil |
| Are there any favorable/unfavorable events affecting the viability of these object(s)? | No | Company declaration | Not Applicable | Nil |
| Is there any other relevant information that may materially affect the decision making of the investors? | No | Company declaration | Not Applicable | Nil |

*Chartered Accountant certificate from Pipara & Co LLP, Chartered Accountants, dated January 14, 2025

#Where material deviation may be defined to mean:

- Deviation in the objects or purposes for which the funds have been raised
- Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents.

CARE Ratings Limited

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai
Phone: +91-22-6754 3456 • www.careedge.in

CIN-L67190MH1993PLC071691

4) Details of objects to be monitored:

(i) Cost of objects –

| Sr. No | Item Head | Source of information / certifications considered by Monitoring Agency for preparation of report | Original cost (as per the Offer Document) in Rs. Crore | Revised Cost in Rs. Crore | Comments of the Monitoring Agency | Comments of the Board of Directors | | |
|--------------|--|--|--|---------------------------|-----------------------------------|------------------------------------|---------------------------|---|
| | | | | | | Reason for cost revision | Proposed financing option | Particulars of - firm arrangements made |
| 1 | Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by our company | Offer Document | 326.00 | NA | Nil | Nil | Nil | Nil |
| 2 | Funding working capital requirements of our company | Offer Document | 220.00 | NA | Nil | Nil | Nil | Nil |
| 3 | General Corporate Purpose | Offer Document | 8.14 | NA | Nil | Nil | Nil | Nil |
| Total | | | 554.14 | NA | | | | |

SB

CARE Ratings Limited

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai
Phone: +91-22-6754 3456 • www.careedge.in

CIN-L67190MH1993PLC071691

HA

(ii) Progress in the objects –

| Sr. No | Item Head | Source of information / certifications considered by Monitoring Agency for preparation of report | Amount as proposed in the Offer Document in Rs. Crore | Amount utilised in Rs. Crore | | | Unutilised amount in Rs. crore | Comments of the Monitoring Agency | Comments of the Board of Directors | |
|--------------|---|--|---|---|---------------------------------|--|--------------------------------|-----------------------------------|------------------------------------|---------------------------|
| | | | | As at beginning of the quarter in Rs. Crore | During the quarter in Rs. Crore | At the end of the quarter in Rs. Crore | | | Reasons for idle funds | Proposed course of action |
| 1 | Prepayment or scheduled re-payment of all or a portion of certain outstanding borrowings availed by our company | CA certificate Offer Document | 326.00 | 326.00 | - | 326.00 | 0.00 | Nil | Nil | Nil |
| 2 | Funding working capital requirements of our company | CA certificate Offer Document | 220.00 | 220.00 | - | 220.00 | 0.00 | Nil | Nil | Nil |
| 3 | General Corporate Purpose | CA certificate Offer Document | 8.14 | 0 | 1.86 | 1.86 | 6.28 | Nil | Nil | Nil |
| Total | | | 554.14 | 546.00 | 1.86 | 547.86 | 6.28 | | | |

SB

CARE Ratings Limited

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai
 Phone: +91-22-6754 3456 • www.careedge.in

CIN-L67190MH1993PLC071691

(iii) Deployment of unutilised IPO proceeds:

| Sr. No. | Type of instrument and name of the entity invested in | Amount invested (Rs. crore) | Maturity date | Earning (Rs. crore) | Return on Investment (%) | Market Value as at the end of quarter |
|---------|---|-----------------------------|---------------|---------------------|--------------------------|---------------------------------------|
| 1. | Axis Public Issue a/c – 924020005512318 | 9.73* | NA | NA | NA | 9.73 |
| 2. | IndusInd Monitoring A/c – 256001800038 | 0.30 | NA | NA | NA | 0.30 |

* Includes Rs.5.98 crore of un-utilised balance of net proceed from IPO and issue expenses of Rs.3.75 crore



CARE Ratings Limited

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai
Phone: +91-22-6754 3456 • www.careedge.in

CIN-L67190MH1993PLC071691



(iv) Delay in implementation of the object(s)

| Objects | Completion Date | | Delay (no. of days/ months) | Comments of the Board of Directors | |
|---|---------------------------|-------------------------|-----------------------------|------------------------------------|---------------------------|
| | As per the offer document | Actual | | Reason of delay | Proposed course of action |
| Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by our company* | By FY24 | 02/15/2024 – 13/09/2024 | * | Nil | Nil |
| Funding working capital requirements of our company | By FY24 | 02/15/2024 – 03/31/2024 | - | Nil | Nil |
| General Corporate Purpose* | By FY24 | Ongoing | * | Nil | Nil |

* Company proposes to deploy the entire Net Proceeds towards the Objects as per the schedule mentioned in the offer document. In the event that the estimated utilization is not completed as per the aforementioned schedule, due to the reasons stated in the offer document, such funds shall be utilised in the next fiscal year, as may be determined by the Company, in accordance with applicable law. Further, the company undertakes to not utilize any spill over from the remaining Objects of the Offer towards our general corporate purposes.

5) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:

| Sr. No | Item Head | Amount in Rs. Crore | Source of information / certifications considered by Monitoring Agency for preparation of report | Comments of Monitoring Agency | Comments of the Board of Directors |
|--------|---------------------------|---------------------|--|-------------------------------|------------------------------------|
| 1. | General Corporate Purpose | 1.86 | CA certificate, Bank Statements and PO | - | Nil |
| | Total | 1.86 | | | |

^ Section from the offer document related to GCP:

"The Company intends to deploy the balance Net Proceeds aggregating up to Rs.8.14 crore in utilizing the proceeds earmarked for general corporate purposes."

CARE Ratings Limited

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai
Phone: +91-22-6754 3456 • www.careedge.in

CIN-L67190MH1993PLC071691

Disclaimers to MA report:

a) This Report is prepared by CARE Ratings Ltd (hereinafter referred to as "**Monitoring Agency/MA**"). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.

b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like statutory auditors (or from peer reviewed CA firms) appointed by the Issuer believed by it to be accurate and reliable.

c) Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.

d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from auditors (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies on in its reports.

e) The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.



CARE Ratings Limited

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai
Phone: +91-22-6754 3456 • www.careedge.in

CIN-L67190MH1993PLC071691